Crumly & Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$951K Buy
793
+8
+1% +$8.17K 0.18% 79
2026
Q1
$722K Buy
785
+8
+1% +$8.11K 0.15% 89
2025
Q4
$835K Sell
777
-8
-1% -$7.65K 0.18% 78
2025
Q3
$599K Buy
785
+186
+31% +$138K 0.13% 96
2025
Q2
$467K Sell
599
-380
-39% -$295K 0.11% 104
2025
Q1
$809K Buy
979
+523
+115% +$435K 0.22% 66
2024
Q4
$352K Hold
456
0.1% 111
2024
Q3
$404K Sell
456
-224
-33% -$201K 0.11% 111
2024
Q2
$616K Sell
680
-177
-21% -$142K 0.18% 78
2024
Q1
$667K Buy
+857
New +$610K 0.18% 74
2021
Q4
Sell
-1,101
Closed -$254K 112
2021
Q3
$254K Buy
1,101
+4
+0.4% +$987 0.12% 94
2021
Q2
$252K Buy
1,097
+4
+0.4% +$803 0.12% 92
2021
Q1
$204K Buy
1,093
+4
+0.4% +$782 0.12% 92
2020
Q4
$224K Buy
+1,089
New +$163K 0.16% 74

Other funds holding LLY

Crumly & Associates's LLY Position: Q2 2026 in Review

Crumly & Associates increased its Eli Lilly (LLY) stake by 1% in Q2 2026, buying an estimated $8.17K and bringing the position to 793 shares worth $951K. The position accounts for 0.18% of the portfolio, ranked #79.

Crumly & Associates first reported a position in LLY in Q4 2020 and has held it in 14 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Crumly & Associates held 793 shares of Eli Lilly worth $951K as of Q2 2026.
  • Crumly & Associates bought 8 Eli Lilly shares in Q2 2026, an estimated $8.17K.
  • Eli Lilly made up 0.18% of Crumly & Associates's portfolio in Q2 2026, its #79 holding.
  • Crumly & Associates first reported a position in Eli Lilly in Q4 2020 and has held it in 14 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Crumly & Associates's 13F filing for Q2 2026, filed 8 Jul 2026.